[go: up one dir, main page]

NO20015701L - 5-Fenyl-pyrimidin-derivater - Google Patents

5-Fenyl-pyrimidin-derivater

Info

Publication number
NO20015701L
NO20015701L NO20015701A NO20015701A NO20015701L NO 20015701 L NO20015701 L NO 20015701L NO 20015701 A NO20015701 A NO 20015701A NO 20015701 A NO20015701 A NO 20015701A NO 20015701 L NO20015701 L NO 20015701L
Authority
NO
Norway
Prior art keywords
phenyl
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Application number
NO20015701A
Other languages
English (en)
Other versions
NO321334B1 (no
NO20015701D0 (no
Inventor
Michael Boes
Guido Galley
Thierry Godel
Torsten Hoffmann
Walter Hunkeler
Patrick Schnider
Heinz Stadler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20015701L publication Critical patent/NO20015701L/no
Publication of NO20015701D0 publication Critical patent/NO20015701D0/no
Publication of NO321334B1 publication Critical patent/NO321334B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
NO20015701A 1999-05-31 2001-11-22 5-Fenyl-pyrimidin-derivater, fremstilling av disse samt anvendelse av disse for fremstilling av medikament for behandling av sykdom. NO321334B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99110482 1999-05-31
PCT/EP2000/004702 WO2000073278A2 (en) 1999-05-31 2000-05-24 5-phenyl-pyrimidine derivatives

Publications (3)

Publication Number Publication Date
NO20015701L true NO20015701L (no) 2001-11-22
NO20015701D0 NO20015701D0 (no) 2001-11-22
NO321334B1 NO321334B1 (no) 2006-04-24

Family

ID=8238270

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015701A NO321334B1 (no) 1999-05-31 2001-11-22 5-Fenyl-pyrimidin-derivater, fremstilling av disse samt anvendelse av disse for fremstilling av medikament for behandling av sykdom.

Country Status (36)

Country Link
US (1) US6756380B1 (no)
EP (1) EP1187814B1 (no)
JP (1) JP3590591B2 (no)
KR (1) KR100478369B1 (no)
CN (1) CN1187338C (no)
AR (1) AR024145A1 (no)
AT (1) ATE273962T1 (no)
AU (1) AU769265B2 (no)
BR (1) BR0011097A (no)
CA (1) CA2375670C (no)
CO (1) CO5170529A1 (no)
CZ (1) CZ20014273A3 (no)
DE (1) DE60013127T2 (no)
DK (1) DK1187814T3 (no)
ES (1) ES2225144T3 (no)
GC (1) GC0000338A (no)
HK (1) HK1046411B (no)
HR (1) HRP20010867A2 (no)
HU (1) HU225016B1 (no)
IL (2) IL146519A0 (no)
JO (1) JO2308B1 (no)
MA (1) MA26794A1 (no)
MX (1) MXPA01011704A (no)
MY (1) MY136258A (no)
NO (1) NO321334B1 (no)
NZ (1) NZ515408A (no)
PE (1) PE20010203A1 (no)
PL (1) PL353492A1 (no)
PT (1) PT1187814E (no)
RU (1) RU2244710C2 (no)
SI (1) SI1187814T1 (no)
TR (1) TR200103460T2 (no)
TW (1) TWI263638B (no)
WO (1) WO2000073278A2 (no)
YU (1) YU85001A (no)
ZA (1) ZA200109496B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
EP1289963B1 (en) 2000-06-13 2005-08-31 Basf Aktiengesellschaft Fungicidal 5-phenyl substituted 2-(cyanoamino) pyrimidines
ATE338544T1 (de) 2000-12-21 2006-09-15 Nitromed Inc Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren
CA2490148A1 (en) 2002-07-02 2004-01-15 F. Hoffmann-La Roche Ag 2, 5-substituted pyrimidine derivatives as ccr-3 receptor antagonists ix
JP4851337B2 (ja) * 2003-11-10 2012-01-11 シンタ ファーマシューティカルズ コーポレーション ヘテロアリールヒドラゾン化合物
JP2007217282A (ja) * 2004-03-04 2007-08-30 Astellas Pharma Inc 置換ピリミジン誘導体
EP1737830A1 (en) * 2004-04-22 2007-01-03 The Procter and Gamble Company Tri-substituted ureas as cytokine inhibitors
JP2008519850A (ja) * 2004-11-10 2008-06-12 シンタ ファーマシューティカルズ コーポレーション Ｉｌ−１２調節化合物
JP2008531509A (ja) 2005-02-25 2008-08-14 エフ．ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
US9013997B2 (en) * 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
PT2988743T (pt) 2013-03-15 2021-03-03 Epigen Biosciences Inc Compostos heterocíclicos úteis no tratamento da doença
GB201316600D0 (en) * 2013-09-18 2013-10-30 Redx Pharma Ltd Agricultural chemicals
JP6609253B2 (ja) * 2014-08-06 2019-11-20 キッセイ薬品工業株式会社 シアノチオフェン誘導体
BR112017016131A2 (pt) 2015-01-30 2018-04-17 Basf Se ?uso de fenilpiridinas, fenilpirimidinas, processos para preparação de fenilpirimidinas e para preparação de composições ativas herbicidas, pirimidinas, composição herbicida, e, método para controlar vegetação indesejada?.
WO2018015180A1 (en) 2016-07-20 2018-01-25 Basf Se Herbicidal compositions comprising phenylpyrimidines
CA3030084A1 (en) 2016-07-25 2018-02-01 Basf Se Herbicidal pyrimidine compounds
AU2017302980A1 (en) * 2016-07-25 2019-01-03 Basf Se Herbicidal pyrimidine compounds
WO2018019555A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyrimidine compounds
US20190269133A1 (en) 2016-07-27 2019-09-05 Basf Se Herbicidal Pyrimidine Compounds
EP3490380A1 (en) 2016-07-28 2019-06-05 Basf Se Herbicidal pyrimidine compounds
WO2018229041A1 (en) 2017-06-14 2018-12-20 Basf Se Herbicidal pyrimidine compounds
WO2019121352A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
WO2019121408A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
WO2019121374A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
WO2019121373A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
AU2019341471A1 (en) * 2018-09-19 2021-04-15 Bayer Aktiengesellschaft Herbicidally active substituted phenylpyrimidine hydrazides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940394A (en) * 1972-03-31 1976-02-24 Santilli Arthur A 2-pyrimidinylthio)alkanoic acids, esters, amides and hydrazides
AR208171A1 (es) 1972-09-29 1976-12-09 Ciba Geigy Ag Procedimiento para la obtencion de nuevos derivados del acido cef-3-em-4-carboxilico
WO1995018124A1 (en) 1993-12-29 1995-07-06 Merck Sharp & Dohme Limited Substituted morpholine derivatives and their use as therapeutic agents
JPH11512399A (ja) 1995-09-01 1999-10-26 シグナル ファーマシューティカルズ，インコーポレイテッド ピリミジンカルボキサミドおよび関連化合物ならびに炎症状態を処置するための方法

Also Published As

Publication number Publication date
IL146519A0 (en) 2002-07-25
AU5070800A (en) 2000-12-18
CA2375670A1 (en) 2000-12-07
ATE273962T1 (de) 2004-09-15
NO321334B1 (no) 2006-04-24
CA2375670C (en) 2009-09-29
TR200103460T2 (tr) 2002-05-21
TWI263638B (en) 2006-10-11
MY136258A (en) 2008-09-30
EP1187814A2 (en) 2002-03-20
MXPA01011704A (es) 2002-05-14
JP3590591B2 (ja) 2004-11-17
HU225016B1 (en) 2006-05-29
HRP20010867A2 (en) 2003-04-30
JP2003500477A (ja) 2003-01-07
HK1046411B (zh) 2005-05-27
KR100478369B1 (ko) 2005-03-24
BR0011097A (pt) 2002-03-19
RU2244710C2 (ru) 2005-01-20
HUP0201527A2 (en) 2002-08-28
DE60013127D1 (de) 2004-09-23
AR024145A1 (es) 2002-09-04
WO2000073278A3 (en) 2001-07-05
ES2225144T3 (es) 2005-03-16
YU85001A (sh) 2004-09-03
JO2308B1 (en) 2005-09-12
CZ20014273A3 (cs) 2002-05-15
HUP0201527A3 (en) 2005-01-28
DK1187814T3 (da) 2004-12-20
AU769265B2 (en) 2004-01-22
IL146519A (en) 2006-12-10
PE20010203A1 (es) 2001-02-15
GC0000338A (en) 2007-03-31
MA26794A1 (fr) 2004-12-20
EP1187814B1 (en) 2004-08-18
PL353492A1 (en) 2003-11-17
ZA200109496B (en) 2003-02-17
CN1187338C (zh) 2005-02-02
KR20020003399A (ko) 2002-01-12
NO20015701D0 (no) 2001-11-22
WO2000073278A2 (en) 2000-12-07
CO5170529A1 (es) 2002-06-27
NZ515408A (en) 2004-02-27
SI1187814T1 (en) 2004-12-31
PT1187814E (pt) 2004-10-29
DE60013127T2 (de) 2005-09-08
HK1046411A1 (en) 2003-01-10
CN1353696A (zh) 2002-06-12
US6756380B1 (en) 2004-06-29

Similar Documents

Publication Publication Date Title
IS2116B (is) 4-fenyl-pyridin afleiður
NO20021077D0 (no) Amino-triazolopyridin-derivater
DE60009747D1 (de) Admantan-derivate
DE50010060D1 (de) Thiazolylamid-derivate
IS6128A (is) 13-Metýl-erýþrómýsín afleiður
DK1187814T3 (da) 5-phenyl-pyrimidinderivater
DE50013404D1 (de) Substituierte 2-dialkylaminoalkylbiphenyl-derivate
NO20021803L (no) Isoksazolkarboksamid-derivater
PT1237857E (pt) Novos derivados fenalquiloxi-fenilo
ATE257148T1 (de) Propargyletherderivate
DK1154988T3 (da) Mevinolinderivater
ATE374747T1 (de) Monofluoralkylderivate
ATE254598T1 (de) 4-hydroxybiphenylhydrazid-derivate
ATE293592T1 (de) Resorcinderivate
DK1187815T3 (da) 4-phenyl-pyrimidinderivater
TR200002831A3 (tr) Kinolin-4-Il türevleri I
DE60025348D1 (de) Ethansulfonyl-piperidin-derivate
NO20022867D0 (no) Syklopentenon-derivater
NO20020212L (no) 3-amino-2-benzyl-1-fenyl-propanderivater
PT1194401E (pt) Derivados de diacil-hidrazina
DE60001736D1 (de) 1-trifluorotmethyl-4-hydroxy-7-piperidinyl-aminomethylchroman-derivate
ATE269328T1 (de) 1-cycloalkylpyrazolyl-benzoyl-derivate

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application